search
Back to results

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Primary Purpose

PTSD

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Ketamine
Midazolam
Sponsored by
VA Office of Research and Development
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for PTSD focused on measuring Post-traumatic Stress Disorder

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • male or female Veterans between the ages of 18 and 75 years
  • diagnosis of PTSD
  • ability to provide written informed consent

Exclusion Criteria:

  • females who are currently pregnant or breastfeeding
  • current high risk for suicide
  • history of moderate/severe head injury
  • history of psychosis
  • current episode of mania/hypomania
  • severe substance and/or alcohol use disorder in the last 6 months

Sites / Locations

  • Minneapolis VA Health Care System, Minneapolis, MNRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Ketamine and prolonged exposure (PE)

Midazolam and prolonged exposure (PE)

Arm Description

Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.

Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.

Outcomes

Primary Outcome Measures

Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
The CAPS-5 is the gold standard in PTSD assessment consisting of a a 30-item structured interview. The CAPS-5 will be recorded and aggregated from all study participants. Range from 0 to 80 with higher score denoting more severe PTSD symptoms.

Secondary Outcome Measures

Full Information

First Posted
September 17, 2020
Last Updated
May 15, 2023
Sponsor
VA Office of Research and Development
search

1. Study Identification

Unique Protocol Identification Number
NCT04560660
Brief Title
Ketamine-enhanced Prolonged Exposure Therapy in PTSD
Official Title
Repeated Ketamine Treatment to Accelerate Efficacy of Prolonged Exposure in PTSD
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 9, 2021 (Actual)
Primary Completion Date
June 18, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
VA Office of Research and Development

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.
Detailed Description
In this single site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine in conjunction with prolonged exposure (PE) therapy for PTSD. Veterans who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of two treatment arms (placebo plus PE vs ketamine plus PE). Participants receive the study drug via intravenous infusion once per week for 3-weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PTSD
Keywords
Post-traumatic Stress Disorder

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Subjects will be randomly assigned to one of two parallel treatment conditions: 1) adjunctive ketamine infusions to prolonged exposure therapy or 2) adjunctive midazolam (active placebo) infusions to prolonged exposure therapy.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
The investigators will use a sequentially numbered, opaque, sealed envelopes, pharmacy-controlled allocations, and coded identical containers for adequate concealment allocation. Administration of study drugs and infusion monitoring will be conducted by research nurse keeping blinding from investigators and independent outcome assessors.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ketamine and prolonged exposure (PE)
Arm Type
Experimental
Arm Description
Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Arm Title
Midazolam and prolonged exposure (PE)
Arm Type
Placebo Comparator
Arm Description
Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.
Intervention Type
Drug
Intervention Name(s)
Ketamine
Intervention Description
FDA approved anesthetic medication with rapid acting antidepressant effects.
Intervention Type
Drug
Intervention Name(s)
Midazolam
Intervention Description
FDA approved sedative medication with dissociative effects.
Primary Outcome Measure Information:
Title
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Description
The CAPS-5 is the gold standard in PTSD assessment consisting of a a 30-item structured interview. The CAPS-5 will be recorded and aggregated from all study participants. Range from 0 to 80 with higher score denoting more severe PTSD symptoms.
Time Frame
CAPS-5 to measure change in PTSD symptoms from baseline to post-treatment (10 weeks)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: male or female Veterans between the ages of 18 and 75 years diagnosis of PTSD ability to provide written informed consent Exclusion Criteria: females who are currently pregnant or breastfeeding current high risk for suicide history of moderate/severe head injury history of psychosis current episode of mania/hypomania severe substance and/or alcohol use disorder in the last 6 months
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paulo R Shiroma, MD
Phone
(612) 725-2000
Ext
612467
Email
Paulo.Shiroma@va.gov
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paulo R Shiroma, MD
Organizational Affiliation
Minneapolis VA Health Care System, Minneapolis, MN
Official's Role
Principal Investigator
Facility Information:
Facility Name
Minneapolis VA Health Care System, Minneapolis, MN
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55417-2309
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gloria Wang, BS
Phone
612-467-2974
Email
gloria.wang2@va.gov
First Name & Middle Initial & Last Name & Degree
Paulo R Shiroma, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

We'll reach out to this number within 24 hrs